CoChat

Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study

Open access
Elhussein, Ahmed, Anderson, Andrea, Bancks, Michael P, Coday, Mace, Knowler, William C, Peters, Anne, Vaughan, Elizabeth M, Maruthur, Nisa M., Clark, Jeanne M, Pilla, Scott · 2022 · The Lancet Regional Health - Americas
Cited by 92

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Among patients with type 2 diabetes, minority racial/ethnic groups have a higher burden of cardiovascular disease, chronic kidney disease, and hypoglycaemia. These groups may especially benefit from newer diabetes medication classes, but high cost may limit access. We examined the association of race/ethnicity with the initiation of newer diabetes medications (GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors). We conducted a secondary analysis of the Look AHEAD (Action for Health in Diabetes) trial including participants with at least one study visit after April 28, 2005. Cox proportional hazards models were used to estimate the association between race/ethnicity and socioeconomic factors with time to initiation of any newer diabetes medication from April 2005 to February 2020. Models were adjusted for demographic and clinical characteristics. Among 4,892 participants, 63.6%, 15.7%, 12.6%, 5.2%, and 2.9% were White, Black, Hispanic, American Indian or Alaskan Native (AI/AN), or other race/ethnicity, respectively. During a median follow-up of 8.3 years, 2,180 (45.2%) participants were initiated on newer diabetes medications. Race/ethnicity was associated with newer diabetes medication initiation (p=.019). Specifically, initiation was lower among Black (HR 0.81, 95% CI 0.70–0.94) and AI/AN participants (HR 0.51, 95% CI 0.26–0.99). Yearly family income was inversely associated with initiation of newer diabetes medications (HR 0.78, 95% CI 0.62–0.98) comparing the lowest and highest income groups. Findings were mostly driven by GLP-1 receptor agonists. These findings provide evidence of racial/ethnic disparities in the initiation of newer diabetes medications, independent of socioeconomic factors, which may contribute to worse health outcomes. NIDDK, NIH

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.lana.2021.100111

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 92

Metadata

Authors
Elhussein, A., Anderson, A., Bancks, M. P., Coday, M., Knowler, W. C., Peters, A., Vaughan, E. M., Maruthur, N. M., Clark, J. M., & Pilla, S.
Venue
The Lancet Regional Health - Americas
Publisher
Elsevier BV
Published
2022-02
Volume
6
Pages
100111
ISSN
2667-193X (ISSN-L)
OpenAlex
W3214063850
Cited by
92
References
11
FWCI
8.72
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study. https://app.cochat.ai/papers/10.1016/j.lana.2021.100111
The paper
Elhussein, A., Anderson, A., Bancks, M. P., Coday, M., Knowler, W. C., Peters, A., Vaughan, E. M., Maruthur, N. M., Clark, J. M., & Pilla, S. (2022). Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study. The Lancet Regional Health - Americas. https://doi.org/10.1016/j.lana.2021.100111

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.